Wednesday, May 22, 2013 Last update: 5:07 AM
Company Tech News as it Breaks
Trade Events
Galectin Therapeutics
News articles for Galectin Therapeutics:
Monday, April 29, 2013
- Galectin Inhibitors Reverse Liver Cirrhosis in Preclinical StudiesNORCROSS, Ga., April 29, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today released data that was presented on April 27, 2013 at the International Liver Congress in Amsterdam, The Netherlands. The data ... read more
Tuesday, February 19, 2013
- Galectin Therapeutics Announces Discovery Program for New Anti-Galectin Drugs in Collaboration with the University of GeorgiaGalectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today the establishment of a collaborative drug discovery ... read more
Thursday, February 7, 2013
- Galectin Therapeutics Executive Chairman, James Czirr to Appear on “The RedChip Money Report” on FOX Business NewsJames Czirr, Executive Chairman of Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, will be a guest on ... read more
Monday, January 28, 2013
- Galectin Therapeutics Inc. Announces Publication of Galectin Symposium Proceedings by the American Chemical SocietyGalectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the American Chemical Society (ACS), as part of ... read more
Tuesday, January 22, 2013
- New Potential Therapy for Diabetic Kidney Disease: Galectin Therapeutics Announces Anti-Galectin Drug is Effective in Preclinical StudiesGalectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced new preclinical data on the efficacy of anti-galectin ... read more
Monday, November 26, 2012
- Galectin Therapeutics Receives US Patent for Second Drug Class to Treat Chronic Liver Disease with Fibrosis (Scarring) and CirrhosisGalectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has received a notice of allowance ... read more